

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * <u>ZDRAVESKI ZORAN</u>  (Last) (First) (Middle) C/O MAGENTA THERAPEUTICS, INC. 50 HAMPSHIRE STREET  (Street) CAMBRIDGE MA 02139  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Magenta Therapeutics, Inc. [ MGTA ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) See Remarks
	3. Date of Earliest Transaction (Month/Day/Year) 12/23/2019	
4. If Amendment, Date of Original Filed (Month/Day/Year) 12/26/2019		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	12/23/2019		M		9	A <sup>(1)</sup>	\$7.71	140,101	D	
Common Stock	12/23/2019		M		4,172	A <sup>(1)</sup>	\$9.49	144,273	D	
Common Stock	12/23/2019		S <sup>(2)</sup>		4,181	D	\$16.0347 <sup>(3)</sup>	140,092	D	
Common Stock	12/24/2019		M		820	A <sup>(1)</sup>	\$7.71	140,912	D	
Common Stock	12/24/2019		S <sup>(2)</sup>		7,902	D	\$16 <sup>(4)</sup>	133,010 <sup>(5)</sup>	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$9.49	12/23/2019		M			4,172 <sup>(1)</sup>	<sup>(6)</sup>	05/08/2028	Common Stock	4,172	\$0.00	129,342	D	
Stock Option (Right to Buy)	\$7.71	12/23/2019		M			9 <sup>(1)</sup>	<sup>(7)</sup>	01/30/2028	Common Stock	9	\$0.00	17,676	D	
Stock Option (Right to Buy)	\$7.71	12/24/2019		M			820 <sup>(1)</sup>	<sup>(7)</sup>	01/30/2028	Common Stock	820	\$0.00	16,856	D	

**Explanation of Responses:**

- Shares were not previously reported on the form 4 filed 12/26/2019 as an option exercise.
- This trade is pursuant to an active 10b5-1 plan.
- This transaction was executed in multiple trades at prices ranging from \$16.00 to \$16.16. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from \$16.00 to \$16.10. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.
- Balance has been updated to reflect the shares acquired and sold on the form 4 filed 12/26/2019.
- This option vests and becomes exercisable in 48 equal monthly installments beginning on the date of effectiveness of the Issuer's Registration Statement on Form S-1.
- This option vests and becomes exercisable in 16 equal quarterly installments beginning on January 1, 2018.

**Remarks:**

Secretary and Chief Legal Officer

/s/Zoran Zdraveski

12/30/2019

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**